成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
机构信息
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
出版信息
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.
COVID-19 伴有体液免疫缺陷患者的管理颇具挑战。我们描述了一例 COVID-19 患者，因抗 CD20 单克隆抗体治疗而多次复发。该患者使用 casirivimab/imdevimab 治疗后成功康复，并检测到中和抗体。该病例提示，对于体液免疫缺陷患者，单克隆抗体具有治疗和预防价值。
Zotero 插件